Credit Suisse Healthcare Conference

N b 11 2014November 11, 2014

Forward Looking Statements and Adjusted Financial Information

This presentation contains forward-looking statements, which are generally statements that are nothistorical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,”“believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking, , , p , , p gstatements are based on management’s current plans, estimates, assumptions and projections, andspeak only as of the date they are made. We undertake no obligation to update any forward-lookingstatement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict andare generally beyond our control Actual results or outcomes may differ materially from those impliedare generally beyond our control. Actual results or outcomes may differ materially from those impliedby the forward-looking statements as a result of the impact of a number of factors, many of whichare discussed in more detail in our Annual Report on Form 10-K and our other reports filed with theSecurities and Exchange Commission.

In addition to financial information prepared in accordance with U.S. GAAP, this presentation alsocontains adjusted financial measures that we believe provide investors and management withsupplemental information relating to operating performance and trends that facilitate comparisonsbetween periods and with respect to projected information. These adjusted measures are non-GAAP and should be considered in addition to but not as a substitute for the information preparedGAAP and should be considered in addition to, but not as a substitute for, the information preparedin accordance with U.S. GAAP. We typically exclude certain GAAP items that management does notbelieve affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may define these measures in different ways. Further informationrelevant to the interpretation of adjusted financial measures, and reconciliations of these adjustedfi i l t th t bl GAAP b f d C l ’ b it t

2

financial measures to the most comparable GAAP measures, may be found on Celgene’s website atwww.Celgene.com in the “Investor Relations” section.

Our Mission and Vision

Celgene is building a preeminent global biopharmaceutical company focused on the

discovery, development and commercialization of innovative therapies for unmet medical needs in

cancer and immune-inflammatory diseases

3

A Leading Global Biopharmaceutical Company

Global, FullyIntegrated

Portfolio ofLeading Products

Unique R&DCapability

• Operations in >60 countries

• Sales in >70 countries

• Manufacturing facilities

• Expertise in hematology, oncology, and immunology

• Diverse technology • Manufacturing facilities in U.S. and EU

• Key research facilities in NJ, CA, MA & Spain

• ~6 000 employees

platforms

• Rich pipeline– 30 programs in

preclinical development– 22 treatments in• ~6,000 employees

globally22 treatments in clinical trials

– 30 pivotal / phase III programs underway

4

Proven Business Model – Moving into its Sweet Spot

Proven Model… Entering its Sweet Spot

1. Unmetneeds

2. Differentiatedproducts Sustainable top and bottom

line growthline growth

P&L operating leverage

Growing cash flowg

More diversified drivers –lower risk profile

3. Leverageinfrastructure

4. Leadingperformance

Growth primarily organic, highly accretive new products

5

Strong, Consistent Revenue and Earnings Growth

Net Product Sales1

($B)EPS3

($)

$2.98$6.4

($B) ($)

25%

$1.89

$2.45

$4.7

$5.4~25%CAGR2 ~31%

CAGR2

$1.04

$1.40$2.6

$3.5

6

2009 2010 2011 2012 2013

Notes: 1) Net Product Sales adjusted for 2008-2011 2) CAGR calculated using 2008 to 2013 3) Adjusted EPS reflects 2014 stock split

2009 2010 2011 2012 2013

Our Business Model Is Proven and Scalable

51.0%51.0%

41.0%41.0%

23 3%23 3%R&DR&D26.0%26.0%23.3%23.3%

21.0%21.0%

R&DR&DSG&ASG&A25.4%25.4%

2009 2010 2011 2012 2013 YTD 2014

4.8%4.8%COGSCOGS8.0%8.0%

7

Adjusted

2009 2010 2011 2012 2013 YTD 2014

Focused on Returns

30.0%

$14 0

$16.0 ROIC

20.0%

25.0%

$10 0

$12.0

$14.0

15.0%

$6 0

$8.0

$10.0

Bill

ion

5.0%

10.0%

$2 0

$4.0

$6.0$ B

Average Invested Capital

0.0%$0.0

$2.0

2008 2009 2010 2011 2012 2013 2014(TTM)

Average Invested Capital

Capital Base Excluding Cash* Capital Base* ROIC Excluding Cash* ROIC

8

GAAP operating income used for all periods, except 2008. Refer to reconciliation tables for ROIC calculation methodology* For purposes of this calculation, cash includes cash and cash equivalents and marketable securities available for sale

Powerful Drivers. Delivering Sustainable Growth.

Our Growth Outlook to 2017

Driving Sustainable Growth

9

Strong Momentum in Core Franchise

Expected 2017 Sales

$7.0B

$

11

$1.5B

Total Hematology $9.5B-$10B

22

$1.5B-$2B

$1.5B-$2B

33

44

Total $13B-$14B

10

R E V L I M I D ® :

Execution and New Indications Accelerate Growth11 2 3 41Key Growth DriversKey Growth Drivers

• Increased duration of therapy and market share growth in RRMM Sales ($B)

1 2 3 4

market share growth in RRMM

• NDMM expansion on-track– EU dossier submitted in February 2014– U.S. submitted in April 2014

Sales ($B)

$7.013%CAGR

• Future drivers advancing – MCL-002 and MDS-005 met endpoint– REMARC phase III in DLBCL first-line

maintenance completed enrollment $4.3p– RELEVANCE phase III in FL completed

enrollment– MAGNIFYTM phase III trial in RR indolent

lymphoma and AUGMENTTM phase III trial in RR FL enrolling

– CLL-002 (CONTINUUM) phase III maintenance trial continues to enroll

2013 2015E 2017E

11

P O M A L Y S T ® / I M N O V I D ® :

Establishing a New Standard in RRMM1 2 3 4

Key Growth DriversKey Growth DriversSales ($B)

1 2 3 4

• Global launch is ongoing– U.S. approval on February 8, 2013– EU approval on August 5, 2013;

reimbursement in key markets

Sales ($B)

$1.5

reimbursement in key markets expected throughout 2014

– Additional global approvals expected

• Increase duration of therapy

35%CAGR 49%CAGR

– Potential strategies to move into 2nd line multiple myeloma

• Combination strategies withProteasome inhibitors $0 3– Proteasome inhibitors

– Monoclonal antibodies– HDAC inhibitors

$0.3

2013 2015E 2017E

12

A B R A X A N E ® :

New Indications for NSCLC & PanC Sustain Growth41 2 3 4

Key Growth DriversKey Growth DriversSales ($B)

41 2 3 4

$1.5-$2.0

• Establishing a new standard of care in metastatic pancreatic cancer

– U.S. approval on September 6, 2013EU approval on December 23 2013

Sales ($B)

– EU approval on December 23, 2013– Additional global approvals expected

• Expanding into new patient segments in core indications

28%CAGR*

$0.65

g– Ph III trials for triple-negative mBC,

adjuvant PanC, and NSCLC maintenance

• Expanding into new cancers in 2014• Expanding into new cancers in 2014– Ph II trials for colorectal and ovarian– Ph I/II combo with anti-PDL-1/PD-1

13

2013 2015E 2017E

Notes: *CAGR calculated using 2017 midpoint

O T E Z L A ® :

Launching in PsA and Psoriasis in 20141 2 3 4

Key Growth DriversKey Growth Drivers Large Underserved

1 2 3 4

PsoriaticA th iti

Patient Populations

~1 0MPsA

• Approvals expected in 2014– U.S.: PsA approved in March; psoriasis

in September– EU: PsA and psoriasis in Q1:15E

Arthritis 1.0M

P i i

• U.S. launch progressing– PsA prescription trends accelerating– Key performance indicators demonstrate

attractive launch dynamics~2.5M

Psoriasis (moderate to severe)

attractive launch dynamics– Sales team for psoriasis executing

• Optimize OTEZLA® opportunity– Ph II trials in IBD and atopic dermatitis

~2.5MAnkylosingSpondylitis

Ph II trials in IBD and atopic dermatitis initiating

– QD formulation

14

Leading Indicators Favorable for Future Growth

PsA Source of Business(based on last therapy prior to OTEZLA®)

Share of New Treatment Starts in PsA

40%

50%

20%

26%17%

19%Biologics

Oral DMARDs

Corticosteroid0%

10%

20%

30%

D th f P ibiP ti t A

26%18%

NSAID

Naïve(No tx in prior 12 months)

0%March

30389

April30690

May34489

June34382

July33583

Aug31481

Sept30284

ENBREL SIMPONI HUMIRA CIMZIASTELARA REMICADE DMARDs OTEZLA

Depth of PrescribingNumber of TRx per Trialist

28%

Patient AccessU.S. National Commercial Formulary Access

Formulary Covered 28%

17%55%

1 TRx2 TRx≥ 3 TRx

98%No Step Through Biologics78%

Note: Symphony data is subject to restatement; Source: Symphony Health Solutions Brand Impact Survey, Sept 201415

0% 20% 40% 60% 80% 100%

GED-0301 Development Highlights

Percentage of Patients AchievingClinical Remission

(CDAI <150 at Day 15 and Maintained for ≥2 weeks)D Di i i

80

100

(CDAI <150 at Day 15 and Maintained for ≥2 weeks)

*P<0.0001 vs. placebo

*

Data Dissemination• First phase II presentation

occurred at UEGW (Vienna) –oral presentation Oct 21

5565

40

60

80*

p• Study results expected to be

published in prestigious medical journal

P U d t10 12

0

20Program Updates• Health authority meetings

underway• Phase III clinical development

The rates of adverse events (AEs) and serious

Placebo GED-0301 10 mg/dayGED-0301 40 mg/day GED-0301 160 mg/day

Phase III clinical development program expected to initiate by year end

16

The rates of adverse events (AEs) and serious adverse events (SAEs) were similar across groups

Source: Presentation at the 22nd United European Gastroenterology Week; October 18-22, 2014; Vienna, Austria.

Powerful Drivers. Delivering Sustainable Growth.

Our Growth Outlook to 2017

Driving Sustainable Growth

17

Complementing Our Internal Strengths with Selected External Partnerships

18

Advancing Novel Programs into Phase I

Key Phase I Studies Planned/Underway:MOR 202 in RRMM and AML

ACY 1215 in RRMMACY-1215 in RRMMEPZ-5676 in MLL-r

AG-221 in IDH2m AMLPDA-002 in PAD

Demcizumab in Solid TumorsCC-90001 in FibrosisCC 90001 in Fibrosis

Novel-Novel DLBCL Combinations

DC IND

19

≥≥3 3 new INDs new INDs targeted per targeted per yearyear

Expanding Phase II Program with New Entities

Over 100 Phase II Trials Planned/Underway:CC-486 Priming in Solid Tumors

CC-122 in Hematologic MalignanciesCC-292 in CLL, NHL and RA

Sotatercept (ACE 011) in MDS Anemia CKDSotatercept (ACE-011) in MDS, Anemia, CKDACE-536 in MDS, Anemia

CC-220 in SLE, Scleroderma and SarcoidosisVTX-2337 in Solid Tumors

DC IND

20

Significant data flow expected in 2014/2015Significant data flow expected in 2014/2015

Broadening Phase III Program

Over 30 Phase III Trials Planned/Underway:REVLIMID® in NDMM NHL and CLLREVLIMID® in NDMM, NHL and CLL

GED-0301 in Crohn’s diseaseABRAXANE® in TNBC, Adjuvant PanC, NSCLC

CC-486 in MDS and AMLSotatercept / Luspatercept (ACE-536) in β-Thalassemia

OTEZLA® in BehçetsOTEZLA in Behçets

DC IND

21

Sustainable growth beyond 2017Sustainable growth beyond 2017

Our Deep Clinical and Development Pipeline

22 Programs in Clinical Developmentg p

100+ Celgene-sponsored Clinical Trials

28 000 E ll d P ti t~28,000 Enrolled Patients

Over 50 Indications

DC IND

22

Accelerating Growth Outlook Through 2017

Net Product Sales($B)

EPS2

($)

$13-$1421%CAGR1

~$7.5026%CAGR

$8.5-$9.5$4.50-$4.75

$6.4$2.98

23

Notes: 1) CAGR calculated using 2017 midpoint 2) Adjusted EPS reflects 2014 stock split

2013 2015E 2017E 2013 2015E 2017E

T H E C E L G E N E S T O R Y

Powerful Business Model, Driving Sustainable Growth

Leveraging Strong Growth Sustainable Trajectory g gPowerful Model

gto 2017

j yBeyond 2017

Leveraging model 4 blockbuster 22 programs– all metrics

improving

More diversifiedl i k

products by 2017

Adjusted EPS expected to grow at 26% CAGR

>50 indications

100+ clinical trials– lower risk 26% CAGR

5-10years

26%CAGR

Adjusted EPS

2013 2015E 2017E

years

24

2013 2015E 2017E

Key Milestones – 2014

Business Milestone Timing

• Submit REVLIMID® for NDMM in the U.S. and EU Q1

Ph III VIDAZA® d t i AML (AZA AML 001) Q2

Hematology

• Ph III VIDAZA® data in AML (AZA-AML-001) Q2

• Initial Ph I data from AZA-ST-001 (CC-486 priming) Q4*

• Ph III REVLIMID® data in non-del 5q MDS Q4*

• Ph I MOR202 data in RRMM H2 → 2015Hematology& Oncology

• Ph I MOR202 data in RRMM H2 → 2015

• Ph II Sotatercept (ACE-011) data in MDS Q4*

• Ph II luspatercept (ACE-536) data in MDS Q4*

• Ph II luspatercept (ACE-536) data in β-thalassemia Q4*uspate cept ( C 536) data β t a asse a Q

• Initial Ph I/II CC-292+REVLIMID® in CLL H2 → 2015

• Ph Ib demcizumab combination data in PanC and NSCLC Q3

• OTEZLA® approval in the U.S. for PsA Q1

I & I

• Ph III OTEZLA® data in ankylosing spondylitis Q2

• OTEZLA® approval in the U.S. for psoriasis Q3

• OTEZLA® CHMP opinion for PsA and psoriasis Q4*p p

• Ph II Sotatercept (ACE-011) data in renal anemia Q4*

25

* Expected

Credit Suisse Healthcare Conference

N b 11 2014November 11, 2014

Reconciliation Tables

010200

9

880.5

776

.7$

(8.2)

(12.7)

(15.9)

-

(0.9)

-

6.8

4.4

34.

7

0.4

9.8

8.3

9.3

-

(0.3)

(0.6)

82.1

64.8

121

.2

34.5

7.3

-

-

-

-

93.9

74.6

15.1

-

-

-

203.2

83.

4

9.7

-

37.

5

-

-

-

-

1.3

1.4

(1.4)

-

-

-

(0.3)

-

(174.9

)

(63.9)

1,310.

5

971.3

$

1.42

1.06

$

mber

31,201

120

1,318.

1$

$

(5.4)

(21.3)

(1.7)

9.8

90.

3

)9.9

13.2

-

104.7

128

.5

8.7

118

.0

-

102.7

15.1

9.8

289.2

(147.5

)

5.1

-

-

0.6

2.0

(2.

9)

(0.7)

)(29

3.3)

1,7

52.9

$

$

1.92

$

$

iaries

Net In

come

Twelv

e Mont

hs En

ded De

cem201

3201

2

1,449.

9

1,456.

2$

-

-

-

-

-

-

18.5

12.4

-

-

-

(1.

6 )

-

-

-

-

144.7

102.4

575.8

189.5

-

-

-

122.5

-

-

162.6

116.2

-

-

-

-

262.8

194.5

171.1

166.4

-

2.6

-

-

80.0

-

-

-

-

-

-

-

-

-

(302.3

)

(198.6

)

2,5

63.1

2,1

62.5

$

3.10

2.51

$

ne Co

rporat

ion an

d Sub

sidi

on of

GAA

P to A

djuste

d N(In

millio

ns, ex

cept pe

r shar

e data

)

YTD Q

2 2014 877

.5$

$

(1)-

(1)-

(2)-

12.0

(3)-

(2)-

(2)-

(4)-

92.8

(5)323

.0

(2)-

(6)-

(7)-

103.0

(8)

25.0

(2)

-

(9)

-

131.0

: n(10

)9.5

(10)

-

(11)

-

(12)

-

(4)

-

(2)

-

-

(2)-

(13)

(121.0

)

1,452.

8$

$

Adjus

ted*

1.80

$

$

Celge

nRe

concili

ati

able to

Celge

ne - G

AAP

justme

nts:

sales:

rod

ucts e

xited it

to be

exited

:n e a

greem

ents a

nd oth

er rev

enue:

on-cor

e reve

nues

s sold

(excl

uding

amort

ization

intangi

ble as

sets):

ed com

pensat

ion ex

pense

nd Ph

armion

invent

ory ste

p-up

exited

it to b

e exite

d:n inte

rcomp

any ro

yalty

d deve

lopme

nt:ed

compen

sation

expen

seolla

boratio

n expe

nseon-

core a

ctivitie

smp

airment

sof

VIDA

ZA ro

yalty o

bligatio

n

ral and

admin

istrativ

e:ed

compen

sation

expen

set of

contin

gent ob

ligation

on-cor

e activ

ities

pricing

settle

ment

of acq

uired in

tangib

le asse

ts:

elated

charg

es and

restru

cturing

, net:

fair va

lue of

contin

gent co

nsider

ation

n and

restru

cturing

costs

proces

s resea

rch an

d deve

lopme

nt

e (exp

ense),

net:

ating a

sset im

pairm

ent, In

c. equi

ty meth

od los

son-

core a

ctivitie

sive

stment

of no

n-core

activi

ties

ing int

erest:

on-cor

e activ

ities

x adju

stment

sabl

e to Ce

lgene

- Adju

sted

mmon

share

attribu

table t

o Celg

ene -

27

Net in

come a

ttribut

a

Befor

e tax a

dj N

et prod

uct s

S

ales o

f pr

Pharm

ion

Ab

raxis

Colla

borativ

e

Abra

xis no

Cost

of go

od

of acq

uired

S

hare-b

ase

Abra

xis an

P

roduct

s e

Ph

armion

Abrax

is

Entr

eMed

Rese

arch a

n d

Shar

e-base

U

pfront

co

Abra

xis no

IP

R&D i

m

Purc

hase o

Selli

ng, ge

ner

Shar

e-base

S

ettlem

ent

Abra

xis no

C

anadia

n p

Amo

rtizatio

n

Acqu

isition

r e

Chan

ge in

Acqui

sition

Acqu

ired in-

p

Othe

r incom

e

Non-

opera

E

ntreM

ed

Abra

xis no

G

ain on

div

Non-

contro

lli

Abra

xis no

Net in

come ta

xNe

t incom

e attri

buta

Net in

come p

er com

Basic

Reconciliation Tables

Celgene Corporation and SubsidiariesR ili ti f GAAP t Adj t d N t I

Explanation of adjustments:(1) Exclude sales related to non-core former Pharmion Corp., or Pharmion, and Abraxis BioScience Inc., or Abraxis products to be divested.(2) Exclude the estimated impact of activities arising from the acquisition of Abraxis that are not related to core nab technology and

were divested in 2011, including other miscellaneous revenues, cost of goods sold (excluding amortization of acquired intangible assets), operating

Reconciliation of GAAP to Adjusted Net Income

expenses and other costs related to such activities. Exclude the net (benefit) cost of activities arising from the acquisition of Pharmion that are planned to be exited.

(3) Exclude acquisition-related inventory step-up adjustments to fair value which were expensed for Abraxis in 2011 and 2010 and Pharmion in 2009 and 2008.(4) Exclude the Company's share of EntreMed, Inc. THALOMID royalties and equity losses. (5) Exclude upfront payments for research and development collaboration arrangements and purchases of intellectual property for unapproved products.(6) Exclude in-process research and development, or IPR&D, impairments.(7) Exclude the purchase of VIDAZA royalty obligations related to unapproved forms.(8) Exclude pricing settlement with the Patented Medicine Prices Review Board of Canada related to sales of THALOMID.(9) Exclude acquisition related charges and restructuring, including changes in the fair value of contingent consideration, related to the acquisitions of

Gloucester, Abraxis and Avila.(10) Exclude the IPR&D write-off related to the acquisition of Pharmion Corp. in 2008.(11) Exclude impairment of royalty receivable asset that was received in 2011 as partial consideration in the sale of the non-core assets obtained by Celgene in the

acquisition of Abraxis.(12) Net income tax adjustments reflect the estimated tax effect of the above adjustments and the impact of certain other non-operating tax adjustments,

including one-time effects of changes in tax law, acquisition related matters, adjustments to the amount of unrecognized tax benefits and deferred taxes on unremitted foreign earnings.

28

Return on Invested Capital Calculation

Return on Invested Capital (ROIC)2014 (TTM) 2013 2012 2011 2010 2009 2008

Operating income 2,093,100 1,808,900 1,746,442 1,442,753 989,635 841,526 (1,464,218) Certain charges (1) 2,043,069

Operating income (non-GAAP for 2008) 2,093,100 1,808,900 1,746,442 1,442,753 989,635 841,526 578,851

Effective tax rate 13% 13% 13% 7% 13% 20% 24%1 826 697 1 575 056 1 512 428 1 339 017 860 221 669 930 439 272Operating income after tax 1,826,697 1,575,056 1,512,428 1,339,017 860,221 669,930 439,272

Total equity 5,768,368 5,589,900 5,694,467 5,512,727 5,995,472 4,394,606 3,491,328 Certain charges (1) 1,979,510 1,979,510 1,979,510 1,979,510 1,979,510 1,979,510 1,979,510 Total debt 6,837,287 4,741,269 3,079,792 1,802,269 1,247,584 - -

Total capital 14,585,165 12,310,679 10,753,769 9,294,506 9,222,566 6,374,116 5,470,838

Total capital beginning of period 12,508,388 10,753,769 9,294,506 9,222,566 6,374,116 5,470,838 3,040,499 Total capital end of period 14 585 165 12 310 679 10 753 769 9 294 506 9 222 566 6 374 116 5 470 838Total capital end of period 14,585,165 12,310,679 10,753,769 9,294,506 9,222,566 6,374,116 5,470,838

Average total capital 13,546,777 11,532,224 10,024,138 9,258,536 7,798,341 5,922,477 4,255,669

ROIC 13.5% 13.7% 15.1% 14.5% 11.0% 11.3% 10.3%

Return on Invested Capital (ROIC), Net of Cash2014 (TTM) 2013 2012 2011 2010 2009 2008

Operating income 2,093,100 1,808,900 1,746,442 1,442,753 989,635 841,526 (1,464,218) Certain charges (1) 2 043 069Certain charges (1) 2,043,069

Operating income (non-GAAP for 2008) 2,093,100 1,808,900 1,746,442 1,442,753 989,635 841,526 578,851

Effective tax rate 14% 13% 13% 7% 13% 20% 24%Operating income after tax 1,826,697 1,575,056 1,512,428 1,339,017 860,221 669,930 439,272

Total equity 5,768,368 5,589,900 5,694,467 5,512,727 5,995,472 4,394,606 3,491,328 Certain charges (1) 1,979,510 1,979,510 1,979,510 1,979,510 1,979,510 1,979,510 1,979,510 Total debt 6 837 287 4 741 269 3 079 792 1 802 269 1 247 584 - -Total debt 6,837,287 4,741,269 3,079,792 1,802,269 1,247,584 Less Cash and Marketable Securities (6,860,700) (5,686,989) (3,900,270) (2,648,154) (2,601,301) (2,996,752) (2,222,091)

Total capital 7,724,465 6,623,690 6,853,499 6,646,352 6,621,265 3,377,364 3,248,747

Total capital beginning of period 6,661,075 6,853,499 6,646,352 6,621,265 3,377,364 3,248,747 3,040,499 Total capital end of period 7,724,465 6,623,690 6,853,499 6,646,352 6,621,265 3,377,364 3,248,747

Average total capital 7,192,770 6,738,595 6,749,926 6,633,809 4,999,315 3,313,056 3,144,623

ROIC, Net of Cash 25.4% 23.4% 22.4% 20.2% 17.2% 20.2% 14.0%

29

,

(1) Excludes $1.7 billion of IPR&D expense in 2008 associated with the acquisition of Pharmion, as well as $300 millionof expense related to the acquisition of intellectual property rights for Vidaza in 2008 prior to it's launch. Amounts adjustedfor tax effects in 2008 are excluded from equity in all years including and subsequent to 2008.

Appendix

Celgene Pipeline

31

Celgene Pipeline

32

Celgene Pipeline

33